techMARK Award

Oxford Biomedica PLC
29 November 2007


FOR IMMEDIATE RELEASE                                           29 NOVEMBER 2007    

                      OXFORD BIOMEDICA WINS TECHMARK AWARD

Oxford, UK: 29 November 2007: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that it has been presented with the techMARK
2007 Achievement of the Year award for its collaboration with sanofi-aventis.
The techMARK Awards, organised by the London Stock Exchange, are designed to
reward outstanding achievement in the technology market. Professor Alan
Kingsman, Oxford BioMedica's Chief Executive Officer, collected the award last
night during the ceremony held at the InterContinental Hotel in London.

Oxford BioMedica announced its collaboration with sanofi-aventis in March 2007
for the global development and commercialisation of TroVax(R), its novel
immunotherapy, for the treatment and prevention of cancers. Under the terms of
this agreement, sanofi-aventis will pay Oxford BioMedica up to €518 million if
all development and registration targets are met for certain defined
indications. Additional payments will be made if regulatory milestones are
achieved in other cancer types. Oxford BioMedica is also entitled to escalating
royalties on global sales of TroVax and to further undisclosed commercial
milestones when net sales of TroVax reach certain levels.

Professor Kingsman commented: 'The sanofi-aventis deal was a transformational
event for Oxford BioMedica that provides both near and long-term value as well
as clear endorsement of our most advanced product. I am honoured to receive this
prestigious award. It is a testament to the achievement of the entire team at
Oxford BioMedica.'

-Ends-

For further information, please contact:
Oxford BioMedica plc:                                  Tel: [phone]
                                                           
Professor Alan Kingsman, Chief Executive
JPMorgan Cazenove Limited:                             Tel: [phone]
                                                           
James Mitford/Gina Gibson
City/Financial Enquiries:                              Tel: [phone]
                                                           
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications

Scientific/Trade Press Enquiries:                      Tel: [phone]
Gemma Price/ Holly Griffiths/ Katja Stout
Northbank Communications


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development and commercialisation of novel therapeutic vaccines and gene-based
therapies with a focus on oncology and neurotherapy. The Company was established
in 1995 as a spin-out from Oxford University, and is listed on the London Stock
Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. In oncology, the lead product candidate
is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to
sanofi-aventis for global development and commercialisation. A Phase III trial
of TroVax in renal cancer is ongoing and two Phase III trials in colorectal
cancer are planned. Oxford BioMedica has two other anti-cancer product
candidates in Phase II development for melanoma and pancreatic cancer
respectively. In neurotherapy, the Company has submitted a Clinical Trial
Application to start a Phase I/II trial of its gene-based treatment for
Parkinson's disease, ProSavin(R). The neurotherapy pipeline also includes
preclinical gene-based therapeutics for vision loss, motor neuron disease and
nerve repair.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 80 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners
include sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibody
therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and
Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline
and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk


2. techMARK Awards

The annual techMARK Awards ceremony and dinner, hosted by the London Stock
Exchange and sponsored by PricewaterhouseCoopers, is one of the largest
gatherings of technology companies in the UK. It is the event to attend for
anybody involved in the UK technology and life sciences markets.



                      This information is provided by RNS
            The company news service from the London Stock Exchange